overview
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics and variant functionalization with our proprietary Maze Compass™.
We are focused on renal, cardiovascular and related metabolic diseases, including obesity, where we believe we can maximize our impact on human health. Using our Maze Compass platform to leverage recent advancements in genetics and drug discovery tools, along with our expertise in variant functionalization, we are developing our precision medicine candidates. Our two lead proprietary programs, MZE829 and MZE782, are novel approaches to treating chronic kidney disease.